Rituximab-Abbs (Truxima) is a biosimilar to Rituximab (Rituxan). Approved 11/28/2018
Rituximab-pvvr (Ruxience) is a biosimilar to Rituximab (Rituxan). Approved 07/23/2019
Rituximab-arrx (Riabni) is a biosimilar to Rituximab (Rituxan). Approved 12/17/2020
- TRADE NAMES: MabThera (Roche); Rituxan (Genentech)
- INDICATIONS: Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rhematoid arthritis (in combination with methotrexate), granulomatosis with polyangiitis and mycroscopic polyangiitis (in combination with glucocorticoids)
- CLASS: Biologic, Biologic disease-modifying antirheumatic drug (bDMARD), CD20-directed cytolytic monoclonal antibody, Disease-modifying antirheumatic drug (DMARD), Immunosuppressant, Monoclonal antibody
- HALF-LIFE: 60 hours (after first infusion)
- FDA APPROVAL DATE: 11/26/1997
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Benazepril, Captopril, Certolizumab, Cisplatin, Clevidipine, Enalapril, Fosinopril, Irbesartan, Lisinopril, Olmesartan, Quinapril, Ramipril
- See adverse reactions attributed to class:
Biologic disease-modifying antirheumatic drug (bDMARD)
FATAL INFUSION REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of rituximab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/09/2026
